Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash from Operations data on file, last reported at 71914000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 71914000.0, down 17.72% year-over-year; the trailing twelve-month figure through Feb 2026 was 260292000.0 (down 35.77% YoY), and the FY2025 annual result was 249465000.0, down 44.55% from the prior year.
• Cash from Operations fell to 71914000.0 in Q1 2026 per NRIX's latest filing, from 67832000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 26689000.0 in Q4 2023 and troughed at 71914000.0 in Q1 2026.
• A 5-year average of 43243235.29 and a median of 42630000.0 in 2022 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 629.37% in 2022, then soared 170.32% in 2023.
• A 5-year view of Cash from Operations shows it stood at 37955000.0 in 2022, then soared by 170.32% to 26689000.0 in 2023, then tumbled by 282.66% to 48751000.0 in 2024, then plunged by 39.14% to 67832000.0 in 2025, then declined by 6.02% to 71914000.0 in 2026.
• Business Quant data shows NRIX's Cash from Operations at 71914000.0 in Q1 2026, 67832000.0 in Q4 2025, and 57385000.0 in Q3 2025.